OncoOne’s Post

We are pleased to have Spexis AG during our London lunch event. Spexis, a Swiss clinical-stage biopharmaceutical company, specializes in rare diseases and cancer. Its lead candidate, ColiFin®, an inhaled therapy for cystic fibrosis, is approved in Europe and advancing to global pivotal Phase 3 studies in early 2023. Leveraging over 25 years and $400 million of research, Spexis aims to deliver transformative therapies while seeking strategic partnerships for product development and market expansion. Additionally, it expands its portfolio through in-licensing or acquisitions, targeting areas with significant unmet medical needs. The Global Rare Disease Treatment Market size was valued at $152bn in 2023 and is poised to grow at a CAGR of 12.8% to reach $400bn by 2031. Our Family is looking closely at their strategy to take a view on this opportunity.   #UCEACapital #investing #familyoffices #London #SPEXIS #Healthcare #oncology #biotech 

Team Octavus Consulting started monthly tracking of catalyst such as PDUFA dates, Patent expiry, Results read-outs and more to keep you all updated on the events to come in coming month. We have covered major highlights here for more details and more highlights you can also reach us at [email protected] #PDUFA #approvals #USFDA #FDA #patentexpiry #readouts #results #catalysts

In the second installment of our recently launched series CATALYST 2024, we present key drug candidates with US PDUFA events in May. Mark your calendars for: KEYTRUDA + PADCEV by Merck and Seagen (acquired by Pfizer), targeting Urothelial Cancer PRADEMAGENE ZAMIKERACEL by Abeona Therapeutics for Recessive Dystrophic Epidermolysis Bullosa ENHERTU by Daiichi-Sankyo and AstraZeneca focusing on Metastatic HER2+ Solid Tumors Stay up-to-date on major clinical developments only with Octavus Consulting! Contact [email protected] for: ·Competitor Monitoring ·Competitive Landscape Analysis ·Clinical Trial Insights ·Competitor Profiling Stay tuned on LinkedIn for industry-related insights and updates! Together, let’s navigate biopharma innovation! #fda #pdufa #drugdevelopment #biotech #pharma #healthcare #octavusconsulting #pharmaceuticalindustry #biotechindustry #keytruda #padcev #prademagenezamikeracel #enhertu

What is the primary driver fueling the #immunecheckpointinhibitor market? The primary driver fueling the immune checkpoint inhibitor market is the rising global prevalence of #cancer, with projections of 26 #million new cases by 2030. Continuous advancements in imaging technologies, such as #CT, #MRI, and #PET, have significantly improved early cancer detection, enabling timely interventions and driving the market's anticipated growth. Want To Know More: https://lnkd.in/d2N6mrjd Key Market Players: Regeneron Pharmaceuticals, Inc., AstraZeneca, BeiGene., Innovent Biologics , GSK , Merck Group., Shanghai Junshi Biosciences Co Ltd , Wohlfahrtsstiftung der F. Hoffmann-La Roche AG., Bristol Myers Squibb #AMR #CancerTreatment #ImmuneCheckpointInhibitors #CancerPrevalence #MedicalAdvancements #EarlyDetection #ImagingTechnologies #CTScan #MRI #PETScan #CancerDiagnosis #HealthcareInnovation

The Antibody-Drug Conjugate (ADC) market is experiencing significant growth, projected to expand at a 30% CAGR, reaching €42.5B by 2030. ADCs represent a significant advancement in targeted cancer therapies, offering enhanced specificity and potency in tumour eradication. Key Highlights: - Robust Pipeline: With over 500 ADC clinical assets, the majority focused on solid tumours, the next 3-5 years will see a wave of phase I/II assets progressing to late-stage clinical trials and market entry. - Innovative Technologies: Advances in linker and payload technologies are driving efficacy and safety, addressing challenges and unlocking new therapeutic potentials. - Strong Industry Momentum: Major pharma companies like Pfizer, AstraZeneca, and Roche are heavily investing in ADCs, reflecting strong confidence in their transformative potential. As the market continue to innovate, ADCs are set to revolutionise cancer treatment, offering new hope to patients worldwide. At Recipharm, a leading CDMO, we partner with pharmaceutical companies to bring their vision to life. Contact us to learn more about how we can support your projects from development to market. #Oncology #Pharma #ADCTherapy #Biotech #Innovation #Healthcare #CDMO #CancerResearch Recipharm

Thoughts on this? >> BioNTech nabs Novartis' Hanekamp as chief commercial officer, terminates Ph1/2 cancer vaccine trial >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharma #pharmaceutical #healthcare

Phesi Unveils Annual Report on Clinical Trials Development Trends for 2023 Phesi's annual analysis of clinical trials in 2023 reveals breast cancer as the most studied disease, followed by solid tumors. COVID-19 trials decreased due to the lack of available patients and a less appealing market. Phase II trials saw a concerning increase in cancellations, which could slow down the development of new therapies. Data-driven approaches and predictive analytics are recommended for trial success in 2024 and beyond, with a focus on trial design, simulation, and digital patient profiles. For more details please click the link! https://lnkd.in/dcijhFXH #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

📢 Astellas Pharma Gastric Cancer Treatment Rejected by FDA Blames CDMO 📢 Astellas' gastric cancer antibody has been rejected by the FDA due to issues with the contract development and manufacturing organization (CDMO). 😞 FDA rejection is a setback for Astellas in their efforts to bring this treatment to patients. 🔍 The rejection highlights the importance of selecting a reliable CDMO for drug development and manufacturing. 🏭 Finding a reputable and experienced CDMO is crucial for the success of biotech companies. 📉 Astellas' stock may be impacted by this FDA rejection news. 💡 Biotech companies should prioritize partnerships with trustworthy CDMOs to avoid regulatory obstacles and delays. #BioprocessUpdates #Astellas #CDMOissues #FDArejection #gastriccancermAb #drugdevelopment #manufacturingorganization #reliableCDMO #biotechcompanies #FDAsetback #regulatoryobstacles #partnerwithtrustworthyCDMOs #Astellasstock #patienttreatment #biotechsuccess #avoiddelays ▷ Full article in our description and here: 📎 https://lnkd.in/d8RW8DN7

Thoughts on this? >> BioNTech nabs Novartis' Hanekamp as chief commercial officer, terminates Ph1/2 cancer vaccine trial >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #healthcare #productmarketing #pharmaceutical

FDA Approves TEPYLUTE, A Novel Formulation to Treat Breast and Ovarian Cancer Jun 28, 2024 BC is highly treatable due to advances in early detection and treatment. Thereby, significantly increases survival rates and treatment success. Shorla Oncology’s TEPYLUTE is a ready-to-dilute injectable formulation of thiotepa. It reduces preparation time and enables accurate dosing. Thiotepa belongs to the group of medicines called alkylating agents. It interferes with the growth of cancer cells, which are eventually destroyed. #researchanddevelopment #innovation #cancertreatment #pharmaceuticals #biotechnology #fdaapproval